Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bet on the placebo

The Phase II trial of Valentis Inc.'s Deltavasc gene therapy may have missed its endpoint in treating peripheral arterial disease (PAD), but the company thinks that all is not lost. The PINC polymer carrier portion of Deltavasc may be at least as efficacious as VLTS's angiogenic Del-1 gene and may provide

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE